Drugs /

gallium ga 68-neob

Back to Drugs List

Overview

NCI Definition [1]:
A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoBOMB1, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope gallium Ga 68, with potential imaging activity during positron emission topography/computed tomography (PET/CT). Upon administration, gallium Ga 68-DOTA-NeoBOMB1 binds to GRPRs present on cancer cells. Upon binding, this radioconjugate can be used to quantify tumor uptake of NeoBOMB1 using PET/CT. GRPR, also known as bombesin receptor subtype 2, is a G-protein-coupled receptor that is overexpressed in some cancer types.

Clinical Trials

View Clinical Trials for gallium ga 68-neob

Gallium ga 68-neob has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating gallium ga 68-neob, 1 is phase 1/phase 2 (1 open).

GRPR Overexpression is the most frequent biomarker inclusion criterion for gallium ga 68-neob clinical trials.

Breast carcinoma, gastrointestinal stromal tumor, and glioblastoma are the most common diseases being investigated in gallium ga 68-neob clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Gallium Ga 68-Neob
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gallium ga 68-neob and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gallium ga 68 neobomb1, gallium ga 68 dota-neobomb1, [68ga]-neob, 68ga-neob
Drug Target(s) [2]:
GRPR
NCIT ID [1]:
C154381

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.